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In order to prepare for the clinical start and to train a group 
of medical physicists, dosimetrists and radiation oncologists, 
working in different centres and with different treatment 
planning systems, in proton treatment planning we started 
the Proton School in January 2012 [3,4]. We have had a 
couple one day face-to-face meetings with lectures and 
workshops, two four day courses and biweekly 
teleconferences. The purpose with the face-to-face meetings 
was to give everyone the same basic knowledge in proton 
treatment and planning. It also gave the students a chance to 
get to know each other, which eases the discussions during 
the teleconferences. Prior to the bi-weekly teleconferences 
the centres were expected to create treatment plans for 
selected patient cases in the proton TPS. Also, as preparation 
for these sessions relevant scientific articles were distributed 
for discussions in the group. During the teleconferences, the 
desktop of the proton TPS was shared for everyone to view 
and/or demonstrate. The teleconferences consist mainly of 
discussions about the suggested plan solutions, patient 
immobilisation, margins, dose distributions and plan 
robustness. The four-day courses were mainly directed to 
dosimetrists and physicists and jointly arranged with Varian 
and with clinical experts to increase the skills in treatment 
planning for protons. Many of the participants of the proton 
school, has also attended other courses, like the PSI winter 
school, ESTROs ion and proton course as well as PTCOG 
meetings and courses. 
Still we are faced with challenges; which patient groups do 
we treat in general, which do we start with? Thinking protons 
instead of photons has been the greatest challenge for the 
group as a whole. How do we create the best plan? This 
includes selecting robust beam angles and thinking about 
what the protons interact with on its way to the target 
volume. Discussions about target volumes has been frequent, 
as the use of them. Delineation is a major issue, not only for 
CTV/PTV but for other structures the protons might interact 
with in its beam path, as well as optimisation structures to 
provide the best plan and thereby “steer” the spots. 
The school has worked out well with active participation both 
in planning and discussing, helping each other in gaining 
experience in a field where we are novices. 
An important step is now to use and produce standardized 
treatment protocols, a treatment planning manual and other 
types of common instructions and check lists so that all seven 
centres create plans in the same technical manner. 
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Proton therapy is a high-precision radiotherapy technique. 
Since 1996,image guided proton therapy (IGPT) has been 
applied at PSI, using the spotscanning technique. Patients are 
positioned and imaged remotely at a dedicatedCT. In 
addition, the second generation Gantry 2 with an in-room 
sliding CT wastaken into operation in November of 2013. 
Fixation of the head is achieved bybite block or mask. In the 
prone position, we mold a special head support 
whichfacilitates a reproducible and comfortable position for 
fixation. In smallchildren, special care must be taken in 
forming the moulage to ensure that theairways are kept free.  
On a daily basis, a patient’spositioning is checked by means 
of orthogonal CT scout images. When theposition is correct, 
the patient is transported with a robotic transport systemto 
the treatment station, Gantry1, while maintaining the fixed 
position. 
We estimate that our remote patientpositioning method 
facilitates a patient throughput of up to 40% higher thanin-
room positioning, because the often time-consuming process 
of positioningand imaging takes place outside the treatment 
room.  
In addition, and in contrast tophoton therapy, proton therapy 
is very sensitive to range changes. It istherefore important 
that during the daily pre-treatment imaging process,changes 
in the patient’s anatomy (such as weight gain or loss) or body 
cavities(e.g. swelling due to sinusitis) need to be monitored 
and taken into account.  
Based on a comprehensive analysis of300 patients, it has 
been established that we achieve a positioning accuracy 
ofless than 2 mm for head and neck cases. 
After almost 20 years of clinicaloperation, the proton 
delivery system at PSI has proven its reliability. 
In the future, there will be a newchallenge: The spot 
scanning technique will be used with Gantry 2 for targetsin 
motion, as in the lung.  
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In developed countries, the total expenditures on health care 
have shown an almost continued increase over the last 
decades, and, not unexpectedly, the cost of cancer care has 
not been spared of this steady growth. The economic impact 
of health - and cancer - care can be measured as total 
spending, percent of national gross domestic product (GDP), 
or the cost to care for a single patient.  
In 2010, the European Union member states devoted an 
average of 9.0% of their GDP to health spending, a significant 
increase from the 7.3% spent in 2000, but a slight decline 
compared to the peak of 9.2% reached in 2009, consequence 
of the economic crisis affecting many countries as of the 
middle of 2008. In Europe, cancer care costs consume about 
5% of the global health care budget, ranging between 4.1% 
and 7%. To the best of our knowledge, radiotherapy only 
consumes bout 5% of the global cancer care budget. 
The variation in cancer care expenditures is more striking 
when focusing on the annual amount of money spent per 
capita: whereas the European average is 2,441€, some 
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countries devote around 6,000€ per capita annually, 
compared to others that only spent as little as 350€.  
These increases, along with the global economic crisis, have 
stimulated the interest for more accurate information about 
the exact health care costs and on the way we spent our 
money. Health services research (HSR), a “multidisciplinary 
field of scientific investigation that studies how social 
factors, financing systems, organizational structures and 
processes, health technologies, and personal behaviors affect 
access to health care, the quality and cost of health care, 
and ultimately, our health and well-being” is intended to 
guide the decisions of managers and policy makers about the 
design and implementation of health care programs.  
Heath Technology Assessment (HTA), one component of HSR, 
addresses five central questions related to efficacy, 
effectiveness, efficiency, availability and distribution of 
health care and thus plays an essential role in modern health 
care by supporting evidence-based decision-making in policy 
and practice. Answers to the question of efficiency - or cost-
effectiveness - are typically given by economic evaluations 
(EE). Full EEs involve the quantitative evaluation of both 
costs and outcomes, or consequences, of competing 
interventions. An appropriately performed EE is incremental, 
that is, it measures the extra cost incurred in order to obtain 
the incremental improvement in outcome. Understandably, 
the inputs used to perform such EEs have to be chosen with 
care if one wants to derive results that correctly support 
decision-making on resource allocation. Apart from the 
indispensible data on effectiveness, the accurate 
computation of the cost component is equally important.  
The presentation will zoom in on the above aspects of HSR 
through examples from radiation oncology and evaluate why 
it is important to invest on this type of research. 
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The methodology used to measure cost in economic 
evaluations in healthcare, as in clinical studies, is key to 
determine the health economic study’s robustness. On-going 
literature review, investigating how costing is conducted in 
radiotherapy shows that one third of selected articles did not 
follow any conventional cost accounting methodology 
[Defourny 2015]. This demonstrates the absence of clear 
practices in reporting cost calculation [Graves 2002] and the 
lack of understanding the influence of a cost calculation 
method on final cost results [Doshi, 2006]. 
A feature of the healthcare sector is the coexistence of 
different types of accounting: NHS reimbursement’s billing, 
hospital finance‘s invoices, insurances’ clients’ bills and so 
forth. These similarities tend to create confusion on how to 
implement costing exercises in a clinical study [Kaplan, 
2014]. Cost accounting captures real economic cost not the 
‘financial accounts’ [Mankiw, 2007]. The economic value of 
an expense, commonly known as the opportunity cost, is 
defined as the value of the benefit you could have realized 
by investing the same amount of money in taking the best 
alternative option. Economic theory measures item by 
capturing its opportunity cost in monetary terms. 
Given the interrelated heterogeneous costs in the healthcare 
sector, health economics recommends selecting the relevant 
costs that matches the costing study perspective. Taking all 
other perspectives into account, the societal perspective is 
the most comprehensive approach because it also includes 
the productivity loss of the patient [Drummond 2005]. When 
authors want to inform decision makers about the real cost of 
an intervention, the global cost involved in the delivering of 
treatment, has to be computed, only then is the information 
relevant to explore whether this intervention is cost-efficient 
[Kaplan, 2014]. Conclusively, the relevant evaluation choice 
comes down to what the study wants to determine.  
The method’s choice influences the cost result [Mercier, 
2014]. Authors have to decide on the appropriate costing 
method to use. The choice of sound methodologies will 
facilitate comparisons across studies.Cost accounting 
methods for cost calculation are categorized by an axis 
linking two distinct margins: top-down (activity-based 
costing, ABC) and bottom-up (micro costing). The top-down 
method uses total department expenses as first step to 
untangle the different resource’s costs. The bottom-up 
approach records individual expenses and cumulates it per 
resource types. The advantages of the bottom-up approach 
were merged in a top-down framework in the time-driven 
activity-based costing (TDABC). ABC and micro-costing 
methods assume inherently full resources utilization, only if 
it can be established that the actual number of treatment 
courses delivered by an RT unit is using all the available 
resources, is the result of these cost accounting models 
robust. In contrast, TD ABC method does not start off with 
this premise. By incorporating the actual resource usage rate 
with the state of the art one, this cost method reveals areas 
for the improvement in the allocation of resources. 
Developing a study calculating the real cost of delivering an 
intervention will contribute to “solving the healthcare 
expenses crisis” [Kaplan 2014].  
To conclude, costing methods have to be relevant, sound and 
transparent to be a useful tool to decision maker [Sullivan, 
2011].  
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The field of radiotherapy is innovating rapidly. These 
innovations are often associated with better health, but also 
with higher costs. As healthcare budgets are scarce, we are 
increasingly asked to show that the effects of new 
radiotherapy techniques are worth the extra costs. In this 
presentation I will explain how to undertake such an analysis.  
This presentation provides an introduction to the principles 
and practice of economic evaluation. Topics include different 
types of economic evaluation, trial-based and model-based 
economic evaluation, use of quality-adjusted lifeyears and 
interpreting and presenting evidence. Throughout the 
presentation I will provide practical examples from the field 
of radiotherapy.  
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